Royal Bank of Canada Forecasts Strong Price Appreciation for Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology (NASDAQ:PYXS) had its target price upped by Royal Bank of Canada from $7.00 to $10.00 in a report published on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts have also issued reports on the stock. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday. Stephens initiated coverage on Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Pyxis Oncology Stock Down 9.5 %

Shares of PYXS stock opened at $1.90 on Thursday. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The business has a fifty day simple moving average of $3.64 and a 200-day simple moving average of $3.61. The stock has a market cap of $112.99 million, a P/E ratio of -1.84 and a beta of 1.27.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds have recently modified their holdings of PYXS. Fullcircle Wealth LLC bought a new position in shares of Pyxis Oncology in the second quarter valued at $40,000. Intech Investment Management LLC acquired a new position in shares of Pyxis Oncology in the third quarter worth $55,000. SG Americas Securities LLC purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth about $58,000. The Manufacturers Life Insurance Company acquired a new stake in Pyxis Oncology in the second quarter valued at approximately $65,000. Finally, MetLife Investment Management LLC boosted its holdings in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.